BRAVELLE

This brand name is authorized in Ecuador, Estonia, Lithuania, Poland, Singapore, South Africa.

Active ingredients

The drug BRAVELLE contains one active pharmaceutical ingredient (API):

1	Urofollitropin UNII W9BB98U6HP - UROFOLLITROPIN
	Urofollitropin contains a highly purified preparation of urinary FSH extracted from the urine of postmenopausal women. FSH stimulates ovarian follicular growth and development as well as gonadal steroid production in women who do not have primary ovarian failure.
	Read more about Urofollitropin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BRAVELLE Powder and solvent for solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03GA04	Urofollitropin	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29113-12-09
EE	Ravimiamet	1307001, 1307012, 1402782
LT	Valstybinė vaistų kontrolės tarnyba	1026274, 1026596
PL	Rejestru Produktów Leczniczych	100193237
SG	Health Sciences Authority	14420P
ZA	Health Products Regulatory Authority	44/21.10/0763